Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies intended to functionally cure serious viral infectious diseases. Its programs use multiplexed CRISPR/Cas approaches delivered via adeno-associated virus (AAV) to excise latent viral DNA from infected cells, with a lead candidate… - View it on GitHub